177 related articles for article (PubMed ID: 30833003)
1. The Current Status of Immunotherapies in Esophagogastric Cancer.
Ku GY
Hematol Oncol Clin North Am; 2019 Apr; 33(2):323-338. PubMed ID: 30833003
[TBL] [Abstract][Full Text] [Related]
2. The Current Status of Immunotherapies in Esophagogastric Cancer.
Ku GY
Surg Oncol Clin N Am; 2017 Apr; 26(2):277-292. PubMed ID: 28279469
[TBL] [Abstract][Full Text] [Related]
3. PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.
Akin Telli T; Bregni G; Camera S; Deleporte A; Hendlisz A; Sclafani F
Cancer Lett; 2020 Jan; 469():142-150. PubMed ID: 31669518
[TBL] [Abstract][Full Text] [Related]
4. Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies.
De Mello RA; Lordick F; Muro K; Janjigian YY
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():237-247. PubMed ID: 31099644
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer.
Smyth E; Thuss-Patience PC
Oncol Res Treat; 2018; 41(5):272-280. PubMed ID: 29705787
[TBL] [Abstract][Full Text] [Related]
6. Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.
Davidson M; Cafferkey C; Goode EF; Kouvelakis K; Hughes D; Reguera P; Kalaitzaki E; Peckitt C; Rao S; Watkins D; Chau I; Cunningham D; Starling N
Clin Colorectal Cancer; 2018 Sep; 17(3):223-230. PubMed ID: 29980492
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Esophageal and Gastric Cancer.
Kelly RJ
Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
9. Advances in Immunotherapy in Esophagogastric Cancer.
Jazieh K; Yoon H; Zhu M
Hematol Oncol Clin North Am; 2024 Jun; 38(3):599-616. PubMed ID: 38493074
[TBL] [Abstract][Full Text] [Related]
10. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies.
Alsina M; Moehler M; Lorenzen S
Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786
[TBL] [Abstract][Full Text] [Related]
12. From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.
Vrána D; Matzenauer M; Neoral Č; Aujeský R; Vrba R; Melichar B; Rušarová N; Bartoušková M; Jankowski J
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577521
[TBL] [Abstract][Full Text] [Related]
13. Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer.
Park R; Williamson S; Kasi A; Saeed A
Anticancer Res; 2018 Oct; 38(10):5569-5580. PubMed ID: 30275174
[TBL] [Abstract][Full Text] [Related]
14. [Current status and prognosis of immune checkpoint inhibitors for esophageal cancer].
Gao HJ; Shang XB; Yu ZT
Zhonghua Wai Ke Za Zhi; 2019 Oct; 57(10):77-82. PubMed ID: 31510736
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in Esophagogastric Cancer: Treatment Landscape, Challenges, and New Directions.
Balmaceda NB; Kim SS
J Gastrointest Cancer; 2024 Mar; 55(1):153-167. PubMed ID: 38127239
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival.
Knief J; Lazar-Karsten P; Hummel R; Wellner U; Thorns C
Pathol Res Pract; 2019 Jun; 215(6):152402. PubMed ID: 31043352
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in gastroesophageal cancers: Current state and future directions.
Shaikh H; Kamran A; Monga DK
J Oncol Pharm Pract; 2021 Mar; 27(2):395-404. PubMed ID: 33050805
[TBL] [Abstract][Full Text] [Related]
18. Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes.
Jones JO; Smyth EC
Cancer Treat Rev; 2020 Mar; 84():101950. PubMed ID: 31918022
[TBL] [Abstract][Full Text] [Related]
19. The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer.
Murphy AG; Kelly RJ
Hematol Oncol Clin North Am; 2017 Jun; 31(3):485-498. PubMed ID: 28501089
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of gastric cancer: Past, future perspective and challenges.
Xie J; Fu L; Jin L
Pathol Res Pract; 2021 Feb; 218():153322. PubMed ID: 33422778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
